Patents by Inventor Matthias Germer

Matthias Germer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating viral infections by administering an antibody preparation comprising IGG, IGA and IGM
    Patent number: 11780909
    Abstract: An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: October 10, 2023
    Assignee: BIOTEST AG
    Inventors: Wolfgang Möller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Matthias Germer, Veit Braun
  • Antibody Preparations
    Publication number: 20210179694
    Abstract: An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.
    Type: Application
    Filed: February 5, 2021
    Publication date: June 17, 2021
    Applicant: BIOTEST AG
    Inventors: Wolfgang Möller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Matthias Germer, Veit Braun
  • IgG, IgA and IgM antibody preparations, method of making and method of use in treatment
    Patent number: 10954290
    Abstract: An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: March 23, 2021
    Assignee: BIOTEST AG
    Inventors: Wolfgang Möller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Matthias Germer, Veit Braun
  • Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer
    Patent number: 10322169
    Abstract: A process for preparing a powder, which includes one or more human coagulation factor proteins and a lactic acid polymer, involves mixing and dispersing a lactic acid polymer with a particle size d50 in the range 0.1-2 ?m and the one or more human coagulation factor proteins in water. The dispersion is dried, and the resulting dried mass is compressed. The resulting compressed dried mass is comminuted to a powder with a particle size d50 in the range of more than 0.5 and up to 5 ?m.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: June 18, 2019
    Assignee: Evonik Roehm GmbH
    Inventors: Juan Tome-Alcalde, Norbert Windhab, Melanie Liefke, Anne Benedikt, Jessica Müller-Albers, Tom Tice, Susanne Ullrich, Andrea Engel, Matthias Germer, Steffen Kistner, Jens Daufenbach
  • Antibody Preparations
    Publication number: 20180319871
    Abstract: An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.
    Type: Application
    Filed: July 9, 2018
    Publication date: November 8, 2018
    Applicant: BIOTEST AG
    Inventors: Wolfgang Möller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Matthias Germer, Veit Braun
  • Antibody preparations
    Patent number: 10059759
    Abstract: An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5 % IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: August 28, 2018
    Assignee: BIOTEST AG
    Inventors: Wolfgang Möller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Matthias Germer, Veit Braun
  • PROCESS FOR PREPARING A POWDER COMPRISING A HUMAN COAGULATION FACTOR PROTEIN AND A LACTIC ACID POLYMER
    Publication number: 20180153967
    Abstract: A process for preparing a powder, which includes one or more human coagulation factor proteins and a lactic acid polymer, involves mixing and dispersing a lactic acid polymer with a particle size d50 in the range 0.1-2 ?m and the one or more human coagulation factor proteins in water. The dispersion is dried, and the resulting dried mass is compressed. The resulting compressed dried mass is comminuted to a powder with a particle size d50 in the range of more than 0.5 and up to 5 ?m.
    Type: Application
    Filed: June 6, 2016
    Publication date: June 7, 2018
    Applicant: Evonik Roehm GmbH
    Inventors: Juan Tome-Alcalde, Norbert Windhab, Melanie Liefke, Anne Benedikt, Jessica Müller-Albers, Tom Tice, Susanne Ullrich, Andrea Engel, Matthias Germer, Steffen Kistner, Jens Daufenbach
  • IMMUNOCONJUGATES TARGETING CD138 AND USES THEREOF
    Publication number: 20170081418
    Abstract: Disclosed are immunoconjugates having in particular specificity for CD138 expressed on target cells and which display homogenous targeting. The immunoconjugates may be sterially hindered and/or contain a cleavable linker.
    Type: Application
    Filed: June 18, 2016
    Publication date: March 23, 2017
    Inventors: Elmar KRAUS, Christoph BRUECHER, Benjamin DAELKEN, Steffen ZENG, Frank OSTERROTH, Christoph UHEREK, Silke AIGNER, Matthias GERMER, Gregor SCHULZ, Thomas HAEDER
  • Antibody Preparations
    Publication number: 20170058020
    Abstract: An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.
    Type: Application
    Filed: November 10, 2016
    Publication date: March 2, 2017
    Applicant: BIOTEST AG
    Inventors: Wolfgang Möller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Matthias Germer, Veit Braun
  • Method for treating psoriasis
    Patent number: 9550831
    Abstract: The present invention provides pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject at most every 3 days.
    Type: Grant
    Filed: September 13, 2010
    Date of Patent: January 24, 2017
    Assignee: BIOTEST AG
    Inventors: Silke Aigner, Matthias Germer, Frank Osterroth, Christoph Uherek, Elmar Kraus, Andrea Wartenberg-Demand, Daniele Wolf, Sibylle Kaiser, Juergen Lindner, Christoph Bruecher, Benjamin Daelken, Gregor Schulz
  • Antibody preparations
    Patent number: 9518110
    Abstract: An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: December 13, 2016
    Assignee: BIOTEST AG
    Inventors: Wolfgang Möller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Matthias Germer, Veit Braun
  • Agent for treating disease
    Patent number: 9512226
    Abstract: The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 10 mg to 200 mg.
    Type: Grant
    Filed: September 13, 2010
    Date of Patent: December 6, 2016
    Assignee: BIOTEST AG
    Inventors: Matthias Germer, Frank Osterroth, Silke Aigner, Christoph Uherek, Elmar Kraus, Andrea Wartenberg-Demand, Daniele Wolf, Sibylle Kaiser, Juergen Lindner, Christoph Bruecher, Benjamin Daelken, Gregor Schulz
  • Methods and agents for improving targeting of CD138 expressing tumor cells
    Patent number: 9446146
    Abstract: Disclosed are immunoconjugates having specificity for CD138 that diminish adhesion of CD138 expressing tumor cells to stroma cells and methods of using the same. This diminished adhesion renders the tumor cells not only susceptible to the immunoconjugate, but also to other agents, in particular cytotoxic agents.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: September 20, 2016
    Assignees: BIOTEST AG, IMMUNOGEN INC., Dana-Farber Cancer Institute
    Inventors: Benjamin Daelken, Christoph Uherek, Kenneth Anderson, Teru Hideshima, Christoph Bruecher, Frank Osterroth, Silke Aigner, Matthias Germer
  • Immunoconjugates targeting CD138 and uses thereof
    Patent number: 9387261
    Abstract: Disclosed are immunoconjugates having in particular specificity for CD138 expressed on target cells and which display homogenous targeting. The immunoconjugates may be sterially hindered and/or contain a cleavable linker.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: July 12, 2016
    Assignees: BIOTEST AG, IMMUNOGEN INC.
    Inventors: Elmar Kraus, Christoph Bruecher, Benjamin Daelken, Steffen Zeng, Frank Osterroth, Christoph Uherek, Silke Aigner, Matthias Germer, Gregor Schulz, Thomas Haeder
  • AGENTS TARGETING CD138 AND USES THEREOF
    Publication number: 20160185854
    Abstract: Disclosed is a human murine chimeric antibody which substantially retains the antigen binding region of its murine counterpart and displays improved binding affinities to the antigen and/or more homogenous binding to target cells.
    Type: Application
    Filed: July 29, 2015
    Publication date: June 30, 2016
    Inventors: Elmar Kraus, Christoph Bruecher, Benjamin Daelken, Matthias Germer, Steffen Zeng, Frank Osterroth, Silke Aigner, Gregor Schulz, Christoph Uherek
  • Method for treating psoriasis
    Patent number: 9334325
    Abstract: The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 0.2 mg to 30 mg.
    Type: Grant
    Filed: September 13, 2010
    Date of Patent: May 10, 2016
    Assignee: BIOTEST AG
    Inventors: Frank Osterroth, Silke Aigner, Matthias Germer, Christoph Uherek, Elmar Kraus, Andrea Wartenberg-Demand, Daniele Wolf, Sibylle Kaiser, Juergen Lindner, Christoph Bruecher, Benjamin Daelken
  • Agents targeting CD138 and uses thereof
    Patent number: 9221914
    Abstract: Disclosed is a human murine chimeric antibody targeting CD138 which substantially retains the antigen binding region of its murine counterpart. The engineered antibody displays improved binding affinities to the antigen and/or more homogenous binding to target cells relative to its murine counterpart. A constant region of the immunoglobulin heavy chain is preferably an IgG4 isotype constant region.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: December 29, 2015
    Assignee: BIOTEST AG
    Inventors: Elmar Kraus, Christoph Bruecher, Benjamin Daelken, Matthias Germer, Steffen Zeng, Frank Osterroth, Christoph Uherek, Silke Aigner, Gregor Schulz
  • Antibody Preparations
    Publication number: 20150064170
    Abstract: An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.
    Type: Application
    Filed: October 31, 2014
    Publication date: March 5, 2015
    Applicant: BIOTEST AG
    Inventors: Wolfgang Möller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Matthias Germer, Veit Braun
  • Antibody preparations
    Patent number: 8900806
    Abstract: An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: December 2, 2014
    Assignee: Biotest AG
    Inventors: Wolfgang Moeller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Matthias Germer, Veit Braun
  • AGENT FOR TREATING DISEASE
    Publication number: 20110059083
    Abstract: The present invention provides pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject at most every 3 days.
    Type: Application
    Filed: September 13, 2010
    Publication date: March 10, 2011
    Inventors: SILKE AIGNER, MATTHIAS GERMER, FRANK OSTERROTH, CHRISTOPH UHEREK, ELMAR KRAUS, ANDREA WARTENBERG-DEMAND, DANIELE WOLF, SIBYLLE KAISER, JUERGEN LINDNER, CHRISTOPH BRUECHER, BENJAMIN DAELKEN